Inclusion Criteria:

          -  Have histologically or cytologically confirmed diagnosis of locally advanced
             metastatic melanoma or cutaneous squamous cell carcinoma that has failed standard
             therapies

          -  For patients treated intratumorally, must have a lesion suitable for direct injection
             of MG1-MAGEA3

          -  Have at least one tumor amenable to biopsy

          -  Have measurable disease via RECIST 1.1 criteria

          -  Adequate organ function and performance status

          -  Additional inclusion criteria present

        Exclusion Criteria:

          -  Prior treatment with any MAGE-A3 vaccine immunotherapy

          -  Prior systemic therapy for cancer within 4 weeks (8 weeks for lung radiation), and has
             recovered from chemo-related toxicities to Grade 1 or less

          -  Intolerant to prior PD1/PD-L1 therapy

          -  Requires use of anti-platelet or anti-coagulant therapy that cannot be safely
             suspended for per protocol biopsies or intra-tumoral injections.

          -  Known active CNS metastases and/or carcinomatous meningitis.

          -  Active autoimmune disease that has required systemic therapy in the past 2 years.

          -  Conditions likely to have resulted in splenic dysfunction.

          -  Known HIV/AIDS, active HBV or HCV infection.

          -  Additional Exclusion criteria exist